Lord, Abbett & Co. LLC Ultragenyx Pharmaceutical Inc. Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$45.8 - $85.4 $502,883 - $937,692	10,980 Added 3.5%	324,724 $19.4 Million
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $3,918 - $5,317	63 Added 0.02%	313,744 $22.8 Million
Q4 2021 Feb 11, 2022	SELL	$73.71 - $87.86 $8.57 Million - $10.2 Million	-116,225 Reduced 27.03%	313,681 $26.4 Million
Q3 2021 Nov 09, 2021	BUY	$77.92 - $102.4 $5.07 Million - $6.67 Million	65,097 Added 17.84%	429,906 $38.8 Million
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $1.2 Million - $1.51 Million	-13,017 Reduced 3.45%	364,809 $34.8 Million
Q1 2021 May 11, 2021	BUY	$106.9 - $167.73 $40.4 Million - $63.4 Million	377,826 New	377,826 $43 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $10.6 Million - $21.1 Million	-273,479 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $19.6 Million - $24.7 Million	273,479 New	273,479 $20.9 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.